

21 October 2021

Japara Shareholders Vote in Favour of Scheme

Japara Healthcare Limited (Japara) (ASX:JHC) announces that Japara shareholders today voted in favour of the scheme of arrangement between Japara and its shareholders (Scheme), which is described in Japara's scheme booklet dated 17 September 2021 (Scheme Booklet), under which Little Company of Mary Health Care Limited (Calvary) will acquire all the issued ordinary shares in Japara.

Voting results

Japara advises that the resolution to approve the Scheme, as set out in the notice of meeting dated 17 September 2021, was passed by the requisite majorities of shareholders, with:

- 89.10% of Japara shareholders present and voting (either in person or by proxy) in favour of the resolution; and
- 89.89% of votes cast in favour of the resolution.

Details of the valid proxies received and votes cast are set out in an attachment to this announcement.

Next Steps

The Scheme remains subject to the approval of the Federal Court of Australia at a hearing scheduled for 10.15am (Melbourne time) on Monday, 25 October 2021 and certain other conditions precedent as described in the Scheme Booklet.

If the Court approves the Scheme, Japara proposes to lodge a copy of the Court orders with the Australian Securities and Investments Commission on the same day (Monday, 25 October 2021), at which time the Scheme will become effective.

The key dates for implementation of the Scheme are set out below*.

Event	Date			
Second Court Date	25 October 2021			
Effective Date	25 October 2021			
Last day of trading in Japara shares on the ASX (Japara shares to be suspended from trading on the ASX from close of trading)	25 October 2021			
Scheme Record Date (for determining entitlements to Scheme Consideration)	7.00pm on 29 October 2021			
Implementation Date (including payment of Scheme Consideration to Japara shareholders)	5 November 2021			

* All times and dates in the above timetable are references to the time and date in Melbourne, Australia and all such times and dates are subject to change. Japara may vary any or all of these dates and times and will provide reasonable notice of any such variation.

For further information:

Investor enquiries:

Media enquiries:

Anthony Rice Chief Financial Officer Japara Healthcare Limited T: (03) 9649 2100

Sue Cato Cato and Clive E: cato@catoandclive.com T: 0419 282 319

This document was authorised for release by Chris Price, Chief Executive Officer & Managing Director.



SCHEME MEETING Thursday, 21 October, 2021

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

	Resolution Voted on at the meeting	Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)				
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	SCHEME RESOLUTION.	NA	122,421,932 89.12%	13,879,897 10.10%	1,070,303 0.78%	61,072	123,512,038 89.89%	13,884,897 10.11%	61,072	Carried

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item